FWPAY — Forward Pharma A/S Share Price
Last trade - 00:00- $0.03m
- -$70.74m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0 | ||
| Price to Tang. Book | 0 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -5.47% | ||
| Return on Equity | -2.53% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2017 | 2018 | 2019 | 2020 | 2021 | 2022E | 2023E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 1,250 | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Forward Pharma A/S is a Denmark-based biopharmaceutical company, that commenced development in 2005 of a formulation of DMF for the treatment of inflammatory and neurological indications. The Company granted to Biogen an irrevocable license to all of its IP through the License Agreement and received from Biogen a non-refundable cash fee of $1.25 billion in February 2017, with the return of EUR 917.7 million to shareholders through a capital reduction in September 2017. The Company has the opportunity to receive royalties from Biogen on Biogen’s net sales of Tecfidera or other DMF products for multiple sclerosis outside the U.S., dependent on, among other things, a favorable outcome in Europe with respect to the 355 Patent Opposition Proceeding, including any appeal thereto.
Directors
- Claus Svendsen CEO (44)
- Thomas Carbone CTR (64)
- Florian Schonharting DRC (53)
- Torsten Goesch DRC (61)
- Jakob Larsen DRC (48)
- Grant Lawrence IND (59)
- Duncan Moore IND (62)
- Last Annual
- December 31st, 2021
- Last Interim
- December 31st, 2021
- Incorporated
- July 1st, 2005
- Public Since
- October 15th, 2014
- No. of Shareholders
- 26
- No. of Employees
- 4
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 343,925.5
- Address
- Oestergade 24A, 1, Copenhagen K, COPENHAGEN, 1100
- Web
- https://forward-pharma.com/
- Phone
- +45 null33444244
- Contact
- Claus Svendsen
- Auditors
- Ernst & Young
Upcoming Events for FWPAY
Similar to FWPAY
Acura Pharmaceuticals
Pink Sheets on Nasdaq
Adhera Therapeutics
Pink Sheets on Nasdaq
Ramoil Management
Pink Sheets on Nasdaq
Adynxx
Pink Sheets on Nasdaq
Aeolus Pharmaceuticals
Pink Sheets on Nasdaq
FAQ
As of Today at 18:08 UTC, shares in Forward Pharma A/S are trading at $400.50. This share price information is delayed by 15 minutes.
Shares in Forward Pharma A/S last closed at $400.50 and the price had moved by -49.58% over the past 365 days. In terms of relative price strength the Forward Pharma A/S share price has underperformed the S&P500 Index by -54.82% over the past year.
There is no consensus recommendation for this security.
Forward Pharma A/S does not currently pay a dividend.
Forward Pharma A/S does not currently pay a dividend.
Forward Pharma A/S does not currently pay a dividend.
To buy shares in Forward Pharma A/S you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $400.50, shares in Forward Pharma A/S had a market capitalisation of $0.03m.
Here are the trading details for Forward Pharma A/S:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: FWPAY
Based on an overall assessment of its quality, value and momentum Forward Pharma A/S is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Forward Pharma A/S. Over the past six months, its share price has underperformed the S&P500 Index by -34.14%.
As of the last closing price of $400.50, shares in Forward Pharma A/S were trading -51.3% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Forward Pharma A/S PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $400.50.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Forward Pharma A/S' management team is headed by:
- Claus Svendsen - CEO
- Thomas Carbone - CTR
- Florian Schonharting - DRC
- Torsten Goesch - DRC
- Jakob Larsen - DRC
- Grant Lawrence - IND
- Duncan Moore - IND